Ben Sasse shines spotlight on daraxonrasib for pancreatic cancer
Revolution Medicines could be on the cusp of a breakthrough. The company expects to soon release results from a Phase 3 trial of its experimental drug that could become the first targeted treatment for pancreatic cancer, the deadliest of the major cancers. Just 13% of people with pancreatic cancer live five years after they’re diagnosed,…